Evaluating miRNA Sequencing and Integrative Proteomics for Identifying Plasma miRNAs as Potential Pharmacodynamic Biomarkers of IFNβ-1a Biologics.

ABSTRACT: We used miRNA sequencing to identify candidate plasma pharmacodynamic (PD) biomarkers of interferon beta-1a (IFNβ-1a) biologics and explored miRNA-mRNA targeted protein relationships and networks to support identified miRNA candidates. Plasma samples from 36 healthy subjects from a placebo-controlled randomized single-dose clinical study with IFNβ-1a and pegIFNβ-1a were used. Mature miRNAs were measured using an in-house miRNA-seq workflow at baseline, at 9 timepoints over 6 days in the IFNβ-1a group (n = 11 [30 μg]), and at 11 timepoints over 13 days in the pegIFNβ-1a group (n = 11 [125 μg]) and placebo-specific groups (n = 6 each). A miRNA was only considered expressed if it had a read count ≥ 10 in more than 50% of the samples across all treatment groups. Linear mixed-effects models (lm

SUBMITTER: Mehanna M 

PROVIDER: S-EPMC12717852 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature